We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. (CPD-DARA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04667663
Recruitment Status : Recruiting
First Posted : December 16, 2020
Last Update Posted : January 25, 2023
Janssen Pharmaceuticals
Information provided by (Responsible Party):
Cancer Trials Ireland

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Actual Primary Completion Date : April 29, 2022
Estimated Study Completion Date : April 30, 2026